Document is current
Any future updates will be listed below
-
Authors
Jin, Hanyong https://orcid.org/0000-0002-5850-0791
Yeom, Ji-Hyun
Shin, Eunkyoung
Ha, Yoonjie https://orcid.org/0000-0002-6506-9338
Liu, Haifeng
Kim, Daeyoung
Joo, Minju
Kim, Yong-Hak https://orcid.org/0000-0001-6192-5996
Kim, Hak Kyun https://orcid.org/0000-0002-7709-7870
Ryu, Minkyung
Kim, Hong-Man
Kim, Jeongkyu https://orcid.org/0000-0002-8550-6654
Kim, Keun P.
Hahn, Yoonsoo https://orcid.org/0000-0003-4273-9842
Bae, Jeehyeon https://orcid.org/0000-0003-1995-1378
Lee, Kangseok https://orcid.org/0000-0002-0060-6884
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2018R1A5A1025077, 2021R1A2C3008934, RS-2024-00353152, 2021R1I1A1A01054464, RS-2023-00248867, 2020R1A2C1005942, 2021R1A2C2094730)
Ministry of Health and Welfare (RS-2024-00339270)
Ministry of SMEs and Startups, Korea
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 16 October 2024
First Online: 28 October 2024
Competing interests
: J.-H.Y., M.J., M.R., and H.-M.K. are employees of NES Biotechnology. J.-H.Y, H.-M.K., M.J., E.S., Y.Ha, M.R., K.L., and J.B. are inventors of KR Patent (Application No. 10-2022-00184521) entitled ‘Anticancer Composition Containing Nanoparticle-tRH Conjugate’. K.L. is an inventor of US Patent (Patent No. US 8871509 B2) entitled “Nanoparticle-based gene delivery systems”. The remaining authors have no conflicts of interest to declare.
